These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22287174)

  • 21. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.
    Lewczuk P; Kornhuber J; Vanmechelen E; Peters O; Heuser I; Maier W; Jessen F; Bürger K; Hampel H; Frölich L; Henn F; Falkai P; Rüther E; Jahn H; Luckhaus Ch; Perneczky R; Schmidtke K; Schröder J; Kessler H; Pantel J; Gertz HJ; Vanderstichele H; de Meyer G; Shapiro F; Wolf S; Bibl M; Wiltfang J
    Exp Neurol; 2010 Jun; 223(2):366-70. PubMed ID: 19664622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment.
    Mamo JC; Jian L; James AP; Flicker L; Esselmann H; Wiltfang J
    Ann Clin Biochem; 2008 Jul; 45(Pt 4):395-403. PubMed ID: 18583625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic study of the toxic effect of oligomeric Aβ1-42 in situ prepared from 'iso-Aβ1-42'.
    Földi I; Datki ZL; Szabó Z; Bozsó Z; Penke B; Janáky T
    J Neurochem; 2011 May; 117(4):691-702. PubMed ID: 21388376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
    Takahashi T; Mihara H
    Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome.
    Tokuda T; Fukushima T; Ikeda S; Sekijima Y; Shoji S; Yanagisawa N; Tamaoka A
    Ann Neurol; 1997 Feb; 41(2):271-3. PubMed ID: 9029078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42.
    Finder VH; Vodopivec I; Nitsch RM; Glockshuber R
    J Mol Biol; 2010 Feb; 396(1):9-18. PubMed ID: 20026079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of peptide biomarker stability in plasma samples using time-course MS analysis.
    Yi J; Liu Z; Gelfand CA; Craft D
    Methods Mol Biol; 2011; 728():161-75. PubMed ID: 21468947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects.
    Slemmon JR; Meredith J; Guss V; Andreasson U; Andreasen N; Zetterberg H; Blennow K
    J Neurochem; 2012 Jan; 120(2):325-33. PubMed ID: 22023354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the brain β-amyloid isoform pattern at different ages of Tg2576 mice.
    Mustafiz T; Portelius E; Gustavsson MK; Hölttä M; Zetterberg H; Blennow K; Nordberg A; Lithner CU
    Neurodegener Dis; 2011; 8(5):352-63. PubMed ID: 21346320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.
    Lui JK; Laws SM; Li QX; Villemagne VL; Ames D; Brown B; Bush AI; De Ruyck K; Dromey J; Ellis KA; Faux NG; Foster J; Fowler C; Gupta V; Hudson P; Laughton K; Masters CL; Pertile K; Rembach A; Rimajova M; Rodrigues M; Rowe CC; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ward V; Martins RN; AIBL Research Group
    J Alzheimers Dis; 2010; 20(4):1233-42. PubMed ID: 20413897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers.
    Päiviö A; Jarvet J; Gräslund A; Lannfelt L; Westlind-Danielsson A
    J Mol Biol; 2004 May; 339(1):145-59. PubMed ID: 15123427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours.
    Lippi G; Brocco G; Salvagno GL; Montagnana M; Guidi GC; Schmidt-Gayk H
    Clin Lab; 2007; 53(7-8):455-9. PubMed ID: 17821951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels.
    Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M
    Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.
    Lachno DR; Emerson JK; Vanderstichele H; Gonzales C; Martényi F; Konrad RJ; Talbot JA; Lowe SL; Oefinger PE; Dean RA
    J Alzheimers Dis; 2012; 32(4):905-18. PubMed ID: 22886018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.
    Varges D; Jung K; Gawinecka J; Heinemann U; Schmitz M; von Ahsen N; Krasnianski A; Armstrong VW; Zerr I
    J Alzheimers Dis; 2011; 23(4):717-26. PubMed ID: 21157024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simple and novel screening assay of natural antioxidants for Cu(II) ion/adrenaline-mediated oxidation of N-terminal amyloid beta by liquid chromatography/mass spectrometry.
    Inoue K; Kaneko M; Hino T; Oka H
    J Agric Food Chem; 2010 Sep; 58(17):9413-7. PubMed ID: 20707367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?
    Sancesario GM; Esposito Z; Nuccetelli M; Bernardini S; Sorge R; Martorana A; Federici G; Bernardi G; Sancesario G
    Exp Neurol; 2010 Jun; 223(2):371-6. PubMed ID: 19664624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.